ライフサイエンスコーパス: recurrence

1 death during treatment or subsequent disease recurrence).

2 patients with breast cancer at high risk of recurrence.

3 BE or dysplasia, and 19 (17%) had dysplasia recurrence.

4 a striking reduction in the time to disease recurrence.

5 eriod, of which none were due to hepatitis B recurrence.

6 nt contributing to drug resistance and tumor recurrence.

7 e risk with this action, however, is seizure recurrence.

8 w therapeutic approaches for limiting tumour recurrence.

9 -positive breast cancer are at high risk for recurrence.

10 h prostate, breast, and head and neck cancer recurrence.

11 EHE and to identify risk factors for post-LT recurrence.

12 ch was associated with increased local tumor recurrence.

13 c disease, were significant risk factors for recurrence.

14 prior to the procedure as predictors for AF recurrence.

15 gene expression may be associated with tumor recurrence.

16 Ipsilateral breast tumor recurrence.

17 le deleterious factors contributing to early recurrence.

18 -established marker for tumor metastasis and recurrence.

19 months should be the target to minimize HCC recurrence.

20 d to have a role in preventing breast cancer recurrence.

21 es including anxious depression and episodic recurrence.

22 rent treatments are associated with frequent recurrence.

23 in macrophages/microglia cells upon disease recurrence.

24 independent effects of DEB-TACE response on recurrence.

25 Gleason scores and prostate-specific antigen recurrence.

26 act was greater in patients with biochemical recurrence.

27 predictive features associated with disease recurrence.

28 No patient developed an orbital recurrence.

29 hed to determine the individual risk for HCC recurrence.

30 tion treatment and a reduction in stroke/TIA recurrence.

31 t strictures, incomplete ablation, and tumor recurrence.

32 TT-OS, and it is not a risk factor for tumor recurrence.

33 s, possibly contributing to local or distant recurrence.

34 to gemcitabine chemotherapy to prevent tumor recurrence.

35 need to be targeted to prevent glioblastoma recurrence.

36 ce was not associated with a reduced risk of recurrence.

37 ut the factors that lead to umbilical hernia recurrence.

38 enter a stem cell-like state, the seeds for recurrence.

39 alcium supplementation on colorectal adenoma recurrence.

40 nd inability to adequately monitor for tumor recurrence.

41 tumor cells that survive and initiate tumor recurrence.

42 ts but none of the group B patients had a VT recurrence.

43 s with shorter survival time or early cancer recurrence.

44 nancy (PTM) are at increased risk for cancer recurrence.

45 urvivors and to observe their occurrence and recurrences.

46 etinoids in prevention of some breast cancer recurrences.

47 .33-1.55) and more pronounced in people with recurrences (2.02; 95% CI, 1.47-2.78).

48 , without significant differences in disease recurrence, 3- or 5-year overall survival(OS) and diseas

49 6 eyes with recurrent pterygium, the risk of recurrence 6 months after CAG was reduced by 55% compare

50 We identified 5,036 recurrences, 7,084 deaths from any cause, and 4,066 deat

51 PV triggers had increased risk of arrhythmia recurrence (83.7% versus 64.0%; P=0.003).

52 rved for post-diagnosis BMI or WHR with late recurrence; a U-shaped association was observed for the

53 ed 191 consecutive patients with biochemical recurrence according to standard acquisition protocols u

54 nts, for 1-year freedom from tachyarrhythmia recurrence after a single ablation procedure of 54% (95%

55 definitive treatment or risk of biochemical recurrence after delayed RP.

56 ntial resection margin on survival and local recurrence after esophagectomy are conflicting.

57 ith increased hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT), but no reli

58 ecurrence, and it may be associated with HCC recurrence after liver transplantation.

59 Mean (SD) time to recurrence after MMS was 3.91 (4.4) years, and after WLE

60 ted biometrics for prediction of local tumor recurrence after renal cell carcinoma ablation.

61 Disease recurrence after surgery and/or radiation and diagnosis

62 ity can effectively reduce the risk of tumor recurrence after surgery, facilitating long-term remissi

63 l prognostic index, Risk Estimation of Tumor Recurrence After Transplant (RETREAT), which incorporate

64 No patients from hereditary NS group had NS recurrence after transplantation.

65 prolonged CLT were independent predictors of recurrences (all P < .05).

66 rrent nodules, maximum recurrence size, bone recurrence, alphafetoprotein at recurrence, donor serum

67 5 to 20 years, the absolute risk of distant recurrence among patients with T1N0 breast cancer was 10

68 went preoperative MR imaging, 14 experienced recurrence and 11 had an identifiable matching control s

69 erculosis had a high cure rate, the cases of recurrence and acquired drug resistance are concerning a

70 han postponing the procedure until the first recurrence and against pleurodesis being used as a reaso

71 ed benefits in terms of reduction of disease recurrence and breast cancer mortality.

72 Recurrence and chemotherapeutic drug resistance are two

73 or to randomization were at a higher risk of recurrence and demonstrated an absolute risk reduction o

74 stance is considered the main cause of local recurrence and distant metastasis in lung cancer.

75 ence suggests that breast cancer initiation, recurrence and drug resistance is supported by breast ca

76 and well-insured women, and reflects fear of recurrence and in some cases misunderstanding of future

77 ancer therapies, which may account for tumor recurrence and metastasis by regenerating new tumors.

78 ACH1 expression had prolonged time to death, recurrence and metastasis, while CD44 was a promising bi

79 analyze variables associated with ICD shock recurrence and mortality after CSD.

80 haracteristics independently associated with recurrence and mortality were advanced heart failure, VT

81 ablation has been associated with reduced VT recurrence and mortality, although it is typically not c

82 ts of vitamin D for preventing breast cancer recurrence and mortality, yet data from prospective coho

83 Three (7%) patients had locoregional recurrence and one (2%) had distant metastasis; 2-year p

84 , we find that IPO11 status predicts disease recurrence and progression to metastasis in patients cho

85 rapy (LRT) on hepatocellular carcinoma (HCC) recurrence and survival after liver transplantation (LT)

86 Long-term follow-up data for disease recurrence and survival was collected in six participati

87 ations for improved understanding of disease recurrence and therapeutic response.

88 Patients who had received chemotherapy for recurrence and those with non-healing wounds or active b

89 using risk ratios (RRs) for number of deaths/recurrences and hazard ratios (HRs), with 95% confidence

90 thin the Milan criteria (71% survival and 6% recurrence), and survival was worse, and recurrence high

91 natomically separate but genetically related recurrence, and (3) multifocal disease with genetically

92 n the study, 791 experienced SBCE, 627 had a recurrence, and 237 died from breast cancer.

93 pic patient-derived xenografts at diagnosis, recurrence, and autopsy.

94 and patients at risk for posttransplantation recurrence, and it may be associated with HCC recurrence

95 ssover rates, blue node metastases, axillary recurrence, and lymphedema as measured by volume displac

96 , duration of ICU and hospital stay, 6-month recurrence, and rehospitalization rates.

97 uenzae (NTHI) are central to the chronicity, recurrence, and resistance to treatment of multiple huma

98 ologic characteristics, lower posttransplant recurrence, and superior survival compared with patients

99 asis, reduced survival, and increased cancer recurrence, and we observe that patients with 11q22.1-q2

100 stillbirths, seven delivery-related fistula recurrences, and one maternal death.

101 HCC recurrence, data on prognosis following recurrence are scarce.

102 etastases in noncrossover nodes and axillary recurrences are low.

103 ons in 64 of 107 patients (59.8%), and local recurrence as well as distant lesions in 25 of 107 patie

104 Hypermutation at diagnosis or at recurrence associated with CD8(+) T cell enrichment.

105 letion has prognostic relevance, with cancer recurrence associated with combined loss of PTEN and FOX

106 e proportion, and incidence ratio of fistula recurrence, associated outcomes, and pregnancy after suc

107 Cumulative probabilities of HCC recurrence at 1 and 5 years were 5.7% and 12.8%, respect

108 of IDH1 was followed by clonal expansion and recurrence at a higher grade.

109 of prostate cancer patients with biochemical recurrence (BCR).

110 an cancer (EOC) has poor prognosis and rapid recurrence because of widespread dissemination of perito

111 3 factors remained independent predictors of recurrence beyond MC (hazard ratio 1.5-2.1, all P < 0.00

112 Although the risk of recurrence beyond MC decreased over time, it never reach

113 ted with a reduced rate of colorectal cancer recurrence, but it was associated with a reduced rate of

114 o Milan criteria (explant) in predicting HCC recurrence by the net reclassification index (P < .001).

115 luated the ratio of observed to expected HCC recurrence by tumor size.

116 or higher that were highly predictive of HCC recurrence (C statistic, 0.77).

117 tant, as these strokes have a high chance of recurrence, can be life threatening, and can lead to equ

118 ctreotide had a significantly lower GI bleed recurrence compared with historical controls not treated

119 o the surgical cavity improved time to local recurrence compared with that for surgical resection alo

120 1.31, P = 0.039), who demonstrated increased recurrence compared with untreated patients in multivari

121 d to evade current therapies and cause tumor recurrence, contributing to poor patient survival.

122 opathologic predictors of posttransplant HCC recurrence, data on prognosis following recurrence are s

123 ulizumab: 10 from day 0 and 2 at the time of recurrence (days 6 and 25).

124 elded 1- and 3-year cumulative incidences of recurrence, defined by positive serum HBsAg, of 2.9% (up

125 Ten-year regional recurrence did not differ significantly between the 2 gr

126 e size, bone recurrence, alphafetoprotein at recurrence, donor serum sodium, and pretransplant recipi

127 Purpose Fear of cancer recurrence (FCR) is a common problem experienced by canc

128 th metastatic melanoma who developed disease recurrence following an initial, unequivocal radiologic

129 Lymph node recurrence following CRLM resection was associated with

130 Recurrences following ablation can occur, particularly i

131 Local recurrences following brachytherapy are uncommon 5 years

132 ophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B after l

133 al, breast cancer-free interval, and distant recurrence-free interval.

134 R0 resection (88% vs 88%, P = 0.999), median recurrence-free survival (33 vs 27 months, P = 0.502), a

135 promoter mutations, correlated with reduced recurrence-free survival (P = 0.001).

136 iated with low survival (P < 0.0001) and low recurrence-free survival (P = 0.007).

137 Recurrence-free survival (RFS) and cancer-specific survi

138 factors were independent predictors of worse recurrence-free survival (RFS), namely, an NLR >/= 5 (P

139 ogic prognostic factors (10-year biochemical recurrence-free survival [bRFS], 29%; distant metastasis

140 ma recurred in 11 patients (25%), with a 64% recurrence-free survival and 59% overall survival at 3 y

141 ts with CSCC and CPNI had poorer mean 5-year recurrence-free survival and disease-specific survival c

142 Recurrence-free survival and recurrence rates.

143 tio of less than 1 showed dramatically lower recurrence-free survival than did patients with a ratio

144 c survival compared with patients with IPNI (recurrence-free survival, 61% vs 76%; P = .009; disease-

145 breast cancers was associated with decreased recurrence-free survival, particularly in patients treat

146 cal cohorts, wherein it associated with poor recurrence-free survival.

147 Risks of disease-related outcomes and 5-year recurrence-free, disease-specific, and overall survival.

148 among 106 patients developing posttransplant recurrence from 1984 to 2014, including analysis of recu

149 r end-stage liver disease at LT >23, time to recurrence, >3 recurrent nodules, maximum recurrence siz

150 a strong, independent prognostic factor for recurrence (hazard ratio, 1.78; P=0.005).

151 6% recurrence), and survival was worse, and recurrence highest, for patients with AFP-producing tumo

152 superior 5-year RFS (72%) and lower post-LT recurrence (HR 0.52, P < 0.001) compared with both untre

153 lative incidence of ipsilateral breast tumor recurrence (IBTR) as a first event within 10 years for l

154 (68)Ga-PSMA ligand PET/CT indicated local recurrence in 68 of 107 patients (63.5%), distant lesion

155 5% of patients and for restaging/biochemical recurrence in 75% of patients.

156 OS as therapeutic targets for reducing tumor recurrence in breast cancer patients.

157 e, and tumor architecture to predict disease recurrence in early stage NSCLC from digitized H&E tissu

158 Tumor recurrence in glioblastoma (GBM) is, in part, attributed

159 may have a role in preventing breast cancer recurrence in hormone receptor-positive early-stage brea

160 ficile infection in animal models and reduce recurrence in humans.

161 prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantation (LT) recipients, but

162 ll as with metastatic competence and disease recurrence in multiple clinical cohorts.

163 diagnosis (HR, 3.0; P < 0.001) predicted HCC recurrence in multivariable analysis.

164 CuCl2 PET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse.

165 mor biometrics for prediction of local tumor recurrence in patients with renal cell carcinoma after t

166 Among 871 patients with cancer recurrence in the N0147 trial (472 men [54.2%] and 399 w

167 Conclusion Local tumor recurrence in the NEPTR may be predicted by FA metrics a

168 The primary endpoint was time to local recurrence in the resection cavity, assessed by blinded

169 ltivariate predictors of mortality following recurrence included model for end-stage liver disease at

170 terval between surgery and the date of first recurrence, including disease progression or the develop

171 of daily living, patient global assessment, recurrence, intermediate outcomes of serum urate levels,

172 red both to better quantify their earthquake recurrence intervals and to test competing models of ear

173 ted until now, because intraplate earthquake recurrence intervals are generally long (10s to 100s of

174 Long-term variations in the earthquake recurrence intervals of intraplate faults therefore are

175 ied prehistoric tsunamis, but the timing and recurrence intervals of such events are uncertain.

176 Tumor recurrence is the leading cause of breast cancer-related

177 an criteria, 5-year survival was better, and recurrence lowest, among patients with non-AFP-producing

178 tify patients with respect to local-regional recurrence (LRR).

179 emplacement or that tsunamigenic earthquake recurrence may have been more frequent in the past.

180 aging between 2004 and 2014 with ipsilateral recurrence more than 6 months after definitive surgical

181 Molecular recurrence (MR) was defined as positivity of BCR-ABL tra

182 at reported a disease-related outcome (local recurrence, nodal metastasis, distant metastasis, or dis

183 None of the two true local recurrences occurred at the site of the vessel.

184 ients with baseline dysplastic disease; most recurrences occurred during the first year after CEIM.

185 Recurrences occurred once in the control group and did n

186 The odds of recurrence (odds ratio, 1.13; 95% CI, .94-1.36) were sim

187 tion profiles across 20 drugs, detailing the recurrence of 301 unique resistance alleles across 1934

188 entation (4/22 vs 23/27; P = .0001), with no recurrence of adverse drug reactions in 74%.

189 During 1y-FU in 1687 (45.9%) pts recurrence of AF occurred.

190 The primary outcome was symptomatic recurrence of AF/atrial tachycardia/atrial flutter lasti

191 on containing methyl bromide resulted in the recurrence of an almost forgotten disease.

192 The primary efficacy endpoint was time to recurrence of any mood event during the double-blind per

193 II showed that oral acyclovir decreased the recurrence of any type of herpes simplex virus keratitis

194 0.2-5.8 years), 35 of 110 (32%) patients had recurrence of BE or dysplasia, and 19 (17%) had dysplasi

195 inically studied for treatment of chest wall recurrence of breast cancer, however with various outcom

196 To investigate the incidence of the recurrence of CAIS in the posterior and anterior circula

197 The primary study outcome was survival after recurrence of cancer.

198 graphic (CT) findings that are predictive of recurrence of colonic diverticulitis.

199 epressants may be associated with relapse or recurrence of depression, so the patient should be close

200 a focus in recent years, but the protracted recurrence of disease and unknown adverse ocular and sys

201 l therapy for cHL are at an 85-fold risk for recurrence of disease compared with the general German p

202 n point between monthly and PRN dosing, when recurrence of edema is anticipated in many patients, CRT

203 The most common complication was recurrence of encapsulation with elevated IOP (15.9%).

204 Secondary outcomes included recurrence of endometrial cancer and overall survival.

205 uggest that the initiation, progression, and recurrence of gliomas are driven, at least partly, by ca

206 Retreatment indication was recurrence of intraretinal or subretinal fluid or new he

207 None of the patients developed recurrence of retinoblastoma or systemic metastasis.

208 mbosis or pulmonary embolism, progression or recurrence of superficial vein-thrombosis, and all-cause

209 Recurrence of tachycardia was more likely in patients wi

210 ient clinical outcome, and it is likely that recurrence of the T-cell drivers of allergic immunity ab

211 y patients who are very likely to experience recurrence of their lung cancer.

212 ell-driven skin disease characterized by the recurrence of transient wheals, angioedema, or both for

213 rimary study end point was the time to first recurrence of ventricular tachycardia/ventricular fibril

214 ythmogenic substrate reduces or prevents the recurrence of ventricular tachycardia/ventricular fibril

215 ary vein reconnection (PVR) still determines recurrences of atrial fibrillation after contact force (

216 perior to antiarrhythmic drugs in preventing recurrences of nonparoxysmal atrial fibrillation and red

217 rade disease; the corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22

218 ity was associated with an increased risk of recurrence or death (hazard ratio, 4.9; P=4.4x10(-4)), w

219 ity was associated with an increased risk of recurrence or death, a finding that supports the potenti

220 iven continuously for 1 year, unless disease recurrence or new breast cancer, intolerable adverse eve

221 ebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1.4%, 95%

222 Metastasis, biochemical recurrence, overall survival, prostate cancer-specific s

223 ess likely to be associated with biochemical recurrence (P = 0.028).

224 ide the Milan criteria (40% survival and 42% recurrence; P < .001).

225 Predicting recurrence patterns may guide treatment recommendations.

226 , length of stay odds ratio 1.11; and hernia recurrence: porcine cadaveric mesh odds ratio 5.18, drin

227 hs) wait times and an increased risk for HCC recurrence post-LT.

228 retrospective study of 46 patients with HCV recurrence posttransplant.

229 implantation tumor development, local tumor recurrence, presence of metastatic disease after surgery

230 nds to C. difficile toxin B (TcdB), reducing recurrence presumably by limiting epithelial damage and

231 For local recurrence, pretreatment imaging features were not progn

232 e pattern of circulating miRNAs may identify recurrence prior to radiological detectability while pro

233 Hernia recurrence rate after 24 months was 2.4% for the Progrip

234 ronic postoperative inguinal pain (CPIP) and recurrence rate after Lichtenstein hernioplasty.

235 ior ROP), the disadvantages are that the ROP recurrence rate is higher, and vigilant and extended fol

236 8 months of follow-up, the atrial arrhythmia recurrence rate was 15% after 1.4 +/- 0.5 procedures per

237 Hernia recurrence rate was 17% (n = 16).

238 The hernia recurrence rate was 6.0% (n = 20) at a mean 3.1 years af

239 Group BDLT, respectively; P = 0.407) and HCC recurrence rates (10.9% and 11.2% for Group LDLT and Gro

240 elanoma margins are difficult to assess, and recurrence rates are high with traditional techniques.

241 al polyposis frequently require surgery, and recurrence rates are high.

242 Despite higher local-recurrence rates for BCS, surgical type does not influen

243 CAG-treated eyes had half the recurrence rates of AMT-treated eyes.

244 become an important therapy for AF; however, recurrence rates remain high.

245 d of achieving excellent outcomes with lower recurrence rates was higher with LMR than with FS.

246 The estimated local recurrence rates were 1.4% at 5 years, 1.8% at 7.5 years

247 aged skin on the head and neck has favorable recurrence rates when melanoma margins are difficult to

248 e associated with increased umbilical hernia recurrence rates.

249 Recurrence-free survival and recurrence rates.

250 Tumor recurrence remains the main reason for breast cancer-ass

251 ell plasticity promotes metastasis and tumor recurrence, resulting in patient mortality.

252 nderlying aetiology, theranostic strategies, recurrence risk and path to recovery are populated by a

253 .1, all P < 0.001) and accurately stratified recurrence risk beyond MC, ranging from 19% (CRS 0) to 6

254 on, a validated model of posttransplantation recurrence risk was produced with a concordance statisti

255 serve as imaging biomarkers of breast cancer recurrence risk.

256 nd combined polymorphisms, the above similar recurrence risks were particularly higher among patients

257 subnetworks in rMDD patients at high risk of recurrence (rrMDD).

258 etween imaging features and Oncotype DX test recurrence score (ODxRS), and post hoc pairwise comparis

259 vival, defined as time from randomization to recurrence, second primary cancer, or death.

260 esponse to LRT independently predict post-LT recurrence, serving as a surrogate for underlying tumor

261 to recurrence, >3 recurrent nodules, maximum recurrence size, bone recurrence, alphafetoprotein at re

262 developed locoregional metastasis as a first recurrence some time after primary diagnosis (recurrent;

263 is associated with poor survival and higher recurrence, studies looking at the role of the circumfer

264 d low stromal PTEN exhibit a shorter time to recurrence than those whose tumors express low levels of

265 are not detected during surgery, leading to recurrences that negatively impact survival.

266 s complications and increased risk of cancer recurrence through systemic inflammatory effects.

267 e non-repeating within the expected Poincare recurrence time of an isolated system, and innovation as

268 ty score matching of factors known to affect recurrence to assess independent effects of DEB-TACE res

269 nce from 1984 to 2014, including analysis of recurrence treatment modality on survival.

270 ated epirubicin would improve time to tumour recurrence (TTR); and whether use of oral capecitabine i

271 atment of a PSH is notoriously difficult and recurrences up to 20% have been reported despite the use

272 suggest a potential increase in liver cancer recurrence upon use of DAAs.

273 yzed for ITT-OS using a Cox model; and tumor recurrence using 2 competitive risk models.

274 ations with overall survival time and cancer recurrence using Kaplan-Meier curves.

275 rall survival, distant metastases, and local recurrence using only clinical factors, clinical factors

276 Median time to recurrence was 14 months, and median follow-up for contr

277 (14-365 months), while median time to local recurrence was 43 months (9-185 months).

278 The incidence rate of dysplasia recurrence was 5.2 per 100 person-years overall (95% CI

279 Statin use in the year preceding recurrence was associated with a reduced risk of cancer-

280 Recurrence was defined as a lid height less than 50% of

281 Molecular recurrence was defined as loss of MMR (BCR-ABL1:ABL1 rat

282 ompletely ablated tumors, intrahepatic tumor recurrence was observed at 2-18 months.

283 Partial recurrence was observed during follow-up in a patient tr

284 Tachycardia recurrence was observed in 54% of the patients after a t

285 Hazard of disease progression or recurrence was significantly increased for patients with

286 Treatment response and recurrence were analyzed with uni- and multivariate stat

287 Imaging responses and posttransplantation recurrence were compared with demographics, liver functi

288 Independent predictors of seizure recurrence were epilepsy duration before remission, seiz

289 ariate predictors of mortality following HCC recurrence were identified to develop a risk score model

290 A total of 361 instances (83%) of disease recurrence were observed after a median follow-up of 54

291 Risk factors for recurrence were older age, female sex, and comorbidity.

292 ergone surgery for GISTs with a high risk of recurrence were randomized to receive adjuvant imatinib

293 further episodes of intraocular/extraocular recurrence were recorded, and all patients were free fro

294 therapies and oral corticosteroids; however, recurrences were common.

295 d AFP score>2 were independent predictors of recurrence, whereas LT type was not.

296 erve, and the prediction of early (<2 years) recurrence, which reflects the intrinsic aggressiveness

297 t-MORAL were superior to Milan at predicting recurrence with c-statistics of 0.82 and 0.87, compared

298 n to documentation of symptom resolution and recurrence within 3 months.

299 ies to uncover mechanisms leading to disease recurrence within each individual patient are warranted.

300 ctive in preventing posttransplantation aHUS recurrence, yet may not fully block AMR pathogenesis.